UBS Group’s X4 Pharmaceuticals XFOR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.1M Buy
267,340
+263,211
+6,375% +$986K ﹤0.01% 5479
2025
Q4
$16.5K Sell
4,129
-155,706
-97% -$566K ﹤0.01% 7915
2025
Q3
$547K Buy
159,835
+49,876
+45% +$129K ﹤0.01% 6030
2025
Q2
$209K Sell
109,959
-57,947
-35% -$237K ﹤0.01% 6693
2025
Q1
$1.19M Buy
167,906
+137,137
+446% +$1.89M ﹤0.01% 5135
2024
Q4
$678K Buy
30,769
+22,065
+254% +$352K ﹤0.01% 5634
2024
Q3
$175K Buy
8,704
+6,636
+321% +$138K ﹤0.01% 5975
2024
Q2
$36K Sell
2,068
-2,235
-52% -$73.1K ﹤0.01% 6941
2024
Q1
$179K Buy
4,303
+4,262
+10,395% +$119K ﹤0.01% 5933
2023
Q4
$1.03K Sell
41
-4,717
-99% -$115K ﹤0.01% 8428
2023
Q3
$156K Buy
4,758
+4,674
+5,564% +$204K ﹤0.01% 5537
2023
Q2
$4.9K Sell
84
-3,249
-97% -$167K ﹤0.01% 7492
2023
Q1
$87K Buy
+3,333
New +$97.7K ﹤0.01% 6020
2022
Q4
Sell
-318
Closed -$16K 11202
2022
Q3
$16K Buy
318
+277
+676% +$9.57K ﹤0.01% 7719
2022
Q2
$1K Sell
41
-1
-2% -$38 ﹤0.01% 9983
2022
Q1
$2K Buy
42
+20
+91% +$1.15K ﹤0.01% 9682
2021
Q4
$2K Buy
+22
New +$2.78K ﹤0.01% 9838
2021
Q3
Sell
-4
Closed -$1K 10148
2021
Q2
$1K Sell
4
-129
-97% -$32.4K ﹤0.01% 9199
2021
Q1
$34K Sell
133
-381
-74% -$100K ﹤0.01% 6906
2020
Q4
$99K Buy
514
+142
+38% +$27.9K ﹤0.01% 5697
2020
Q3
$75K Buy
372
+202
+119% +$48.4K ﹤0.01% 5361
2020
Q2
$48K Sell
170
-139
-45% -$38.1K ﹤0.01% 5897
2020
Q1
$93K Sell
309
-180
-37% -$51.1K ﹤0.01% 5349
2019
Q4
$157K Buy
489
+187
+62% +$67.1K ﹤0.01% 5755
2019
Q3
$115K Buy
302
+260
+619% +$103K ﹤0.01% 5690
2019
Q2
$19K Buy
42
+36
+600% +$18.3K ﹤0.01% 6656
2019
Q1
$3K Sell
6
-33
-85% -$18.2K ﹤0.01% 7352
2018
Q4
$16K Buy
39
+20
+105% +$7.63K ﹤0.01% 6954
2018
Q3
$5K Sell
19
-77
-80% -$32.7K ﹤0.01% 7513
2018
Q2
$63K Sell
96
-23
-19% -$75.3K ﹤0.01% 5815
2018
Q1
$491K Buy
119
+1
+0.8% +$2.91K ﹤0.01% 4220
2017
Q4
$270K Buy
+118
New +$298K ﹤0.01% 4715

Other funds holding XFOR